AI-generated summary
The authors reviewed 23 clinical and preclinical studies published from 2015 to 2025 on photobiomodulation dosimetry and outcomes in diabetic neuropathy. They report the most consistent effects with wavelengths of 630-670 nm or 808-904 nm, fluences of 3-10 J/cm², and at least 12 sessions. The authors also note that standardized dosimetry is lacking across studies.
- Studies included
- 23
- Who or what was studied
- Adults with diabetic neuropathy, including type 2 diabetes mellitus; the review also includes preclinical studies
- Wavelengths
- 630, 670, 808, 904 nm
- Limits stated in the abstract
- The abstract notes the absence of standardized dosimetry among the included studies, which limits comparability and reproducibility of protocols.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 630-670 nm, 808-904 nm
- Power
- 100 mW
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Neuropathy, Wound healing, Inflammation, Dosimetry, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.